38 -12 (62) 2023 — Khaitov M.S. — COMPARATIVE ASSESSMENT OF THE EFFECTIVENESS OF HEPATOPROTECTORS IN SLOW DOWN FIBROTIC PROCESSES IN THE LIVER ON A MODEL OF FIBROSIS/CIRRHOSIS

COMPARATIVE ASSESSMENT OF THE EFFECTIVENESS OF HEPATOPROTECTORS IN SLOW DOWN FIBROTIC PROCESSES IN THE LIVER ON A MODEL OF FIBROSIS/CIRRHOSIS

Khaitov M.S. Tashkent Medical Academy (TMA) Uzbekistan

Resume

Liver fibrosis is a dynamic pathological process that develops in chronic liver diseases, the outcome of which may be cirrhosis. The “gold standard” for the diagnosis and treatment of hepatic fibrosis remains biopsy and medications; however, non-invasive diagnostic methods as well as herbal preparations are currently being actively introduced into clinical practice. The article summarizes information about changes in specific direct markers of fibrosis, which causes the accumulation of triglycerides and other fats in liver cells – hepatocytes. The content of fatty acids in hepatocytes depends on the balance between their intake and excretion. In some cases, fatty infiltration causes the death of hepatocytes and progresses into inflammation of the liver (steatohepatitis) with fibrosis, turning into cirrhosis.

Keywords. Non-alcoholic fatty liver disease, fibrosis, fatty hepatitis, fatty hepatosis.

First page

207

Last page

215

For citation: Khaitov M.S. – COMPARATIVE ASSESSMENT OF THE EFFECTIVENESS OF HEPATOPROTECTORS IN SLOW DOWN FIBROTIC PROCESSES IN THE LIVER ON A MODEL OF FIBROSIS/CIRRHOSIS //New Day in Medicine 2023 12(62): 207-215 https://newdaymedicine.com/index.php/2023/12/14/l-592/

LIST OF REFERENCES:

1. Бондарева К.С. Клиническая характеристика хронического гепатита и цирроза печени различной этиологии / К.С.Бондарева, П.В.Лебедев // Кубанский научный медицинский вестник. 2013;5:46-51.
2. Mokdad AA, Lopez АD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. // BMC Medicine. 2014;12:145. DOI:10.1186/s12916-014-0145-y
3. Черноусов А.Ф., Хоробрых Т.В., Карпова Р.В. Стимуляция регенерации печени у больных циррозом. – / М.: Практическая медицина, 2017;136.
4. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, et al. Subclinical hepatic encephalopathypredicts thedevelopment ofovert hepaticencephalopathy. // Am J Gastroenterol 2001;96:2718-23.
5. Ивашкин В.Т., Надинская М.Ю., Буеверов А.О. Печеночная энцефалопатия и методы ее метаболической коррекции. // Болезни органов пищеварения. 2001;1:25-7. [Ivashkin V.T., Nadinskaya M.Yu., Bueverov A.O. Hepatic encephalopathy and methods for its metabolic correction. // Bolezni Organov Pishchevareniya. 2001;1:25-7 (In Russ.)
6. Трухан Д.И. Синдром печеночной энцефалопатии. Актуальные аспекты диагностики и лечения // Медицинский совет. 2016;14:80-86.
7. Dyson J. K., Anstee Q. M., McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging // Frontline Gastroenterol. 2014;5(3):211-218.
8. Гарелик П.В., Могилевец Э.В. Фотодинамическая терапия при циррозе печени (экспериментальное исследование) // Анналы хирургической гепатологии, 2015;20(4):17-26.
9. Xu  B.,  Broome U., Uzunel M., Nava S., Ge X., Capillarization of hepatic sinusoid  by  liver  endothelial  cell-reactive  autoantibodies  in patients with cirrhosis and chronic hepatitis. // Am. J. Pathol. 2003;163(4):1275-1289.